Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as standard therapies for advanced nonsmall cell lung cancer (NSCLC) patients with EGFR mutation positive. Because these targeted therapies could cause tumor necrosis and shrinkage, the purpose of the study is to sear...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore)
Hauptverfasser: He, Xiaobo, Zhang, Yang, Ma, Yuxiang, Zhou, Ting, Zhang, Jianwei, Hong, Shaodong, Sheng, Jin, Zhang, Zhonghan, Yang, Yunpeng, Huang, Yan, Zhang, Li, Zhao, Hongyun
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wolters Kluwer Health 2016
Schlagworte:
5700
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979775/
https://ncbi.nlm.nih.gov/pubmed/27495021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004176
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge